The study will evaluate Sinaptica’s SinaptiStim in delivering simultaneous transcranial magnetic and alternating current ...

Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...

The University hospitals of Geneva (HUG), the Department of Health and Mobilities (DSM) of the Canton of Geneva and the Wyss Center for Bio and Neuro Engineering enter into a three-party agreement to ...

“We’re continuing to innovate and evolve our precision neuromodulation therapy to provide the most effective and efficient treatment for patients,” said Giacomo Koch, MD, PhD, Sinaptica ...

Valencia Technologies announced today that it received a strategic investment totaling up to $35 million and appointed a new ...

Overview of the Migraine Drugs MarketThe global Migraine Drugs Market is valued at $6.37 billion in 2024 and is projected to ...

Salvia BioElectronics has reported the first patient implanted with its ultra-thin implant for chronic migraine in The ...

CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that ...

The first patient in the Netherlands has been treated with an innovative implant designed to address chronic migraine, ...

The cardiovascular portfolio grew mid-single-digits, with cardiac ablation solutions reporting 22% growth, driven by the Pulse Field Ablation (PFA) products, Affera and PulseSelect. Management ...